These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 23759980

  • 1. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma.
    Hamamoto J, Soejima K, Yoda S, Naoki K, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Yasuda H, Hayashi Y, Sakamoto M, Takebayashi T, Betsuyaku T.
    Mol Med Rep; 2013 Aug; 8(2):456-62. PubMed ID: 23759980
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ.
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling.
    Fassina A, Cappellesso R, Fassan M.
    Chest; 2011 Nov; 140(5):1305-1311. PubMed ID: 21622546
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens.
    Huang W, Hu J, Yang DW, Fan XT, Jin Y, Hou YY, Wang JP, Yuan YF, Tan YS, Zhu XZ, Bai CX, Wu Y, Zhu HG, Lu SH.
    Am J Respir Crit Care Med; 2012 Dec 01; 186(11):1160-7. PubMed ID: 23043084
    [Abstract] [Full Text] [Related]

  • 9. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis.
    Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J.
    Clin Cancer Res; 2011 Nov 01; 17(21):6802-11. PubMed ID: 21890451
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
    Tian F, Shen Y, Chen Z, Li R, Lu J, Ge Q.
    Gene; 2016 Oct 15; 591(2):338-43. PubMed ID: 27291819
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies.
    Charkiewicz R, Pilz L, Sulewska A, Kozlowski M, Niklinska W, Moniuszko M, Reszec J, Manegold C, Niklinski J.
    Int J Cancer; 2016 Feb 01; 138(3):689-97. PubMed ID: 26311306
    [Abstract] [Full Text] [Related]

  • 17. MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.
    Patnaik S, Mallick R, Kannisto E, Sharma R, Bshara W, Yendamuri S, Dhillon SS.
    J Thorac Oncol; 2015 Mar 01; 10(3):446-53. PubMed ID: 25695220
    [Abstract] [Full Text] [Related]

  • 18. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma.
    Sand M, Skrygan M, Georgas D, Sand D, Hahn SA, Gambichler T, Altmeyer P, Bechara FG.
    J Dermatol Sci; 2012 Dec 01; 68(3):119-26. PubMed ID: 23026055
    [Abstract] [Full Text] [Related]

  • 19. [Differential expression of hsa-miR-126 and hsa-miR-518b in esophageal squamous carcinoma].
    Cai H, Wang JS, Zhang MX, Duan XY, Ma RQ.
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan 01; 31(1):23-7. PubMed ID: 21269950
    [Abstract] [Full Text] [Related]

  • 20. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M.
    Lung Cancer; 2014 Aug 01; 85(2):306-13. PubMed ID: 24928469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.